Congratulations to Agenus' Jeff Tan on being selected as a panelist at Fierce Pharma's New Product Planning Summit.
newproductplanning.com

Today Agenus announced the initiation of the botensilimab ACTIVATE Phase 2 trials, which will initially evaluate botensilimab in microsatellite stable colorectal cancer (MSS CRC) and advanced refractory melanoma.
investor.agenusbio.com/news-releases/…

Agenus is pleased to announce the appointment of Patricia Carlos as Chief Regulatory, Quality, and Safety Officer; and Todd Yancey, MD, as Senior Global Clinical Development, Medical Affairs and Commercial Advisor.
investor.agenusbio.com/news-releases/…

This week we're showcasing the newly redesigned Agenus website. Visit our Join Us page to explore global career opportunities and hear from Agenus employees in their own words why they continue to choose Agenus!

agenusbio.com/join-us/

This week we're showcasing the newly redesigned Agenus website. Explore our Capabilities section to learn about our VISION platform and how it seeks to use advanced analytics to optimize drug design.
agenusbio.com/capabilities/v…

This week we're showcasing the newly redesigned Agenus website. On our homepage you'll find a Spotlight on botensilimab--Agenus' novel adaptive and innate immune activator.
agenusbio.com

This week we're showcasing the newly redesigned Agenus website. Visit to explore our pipeline and discover what makes Agenus a leader in I-O innovation.
agenusbio.com/pipeline/

Agenus is pleased to announce the launch of our newly redesigned website. Follow us this week as we showcase some of its features!

Agenus Provides Corporate Update and Second Quarter 2022 Financial Report
investor.agenusbio.com/news-releases/…

We are “Living Diversity” to drive creativity & inventive power, intentionally #LifeScienceLeader . “We sought out a biopharma enterprise where diversity has always been an operating principle...” CEO Jennifer Buell spoke with Wayne Koberstein & [email protected] lifescienceleader.com/doc/living-div…

Agenus to Participate at BTIG Biotechnology Conference
investor.agenusbio.com/news-releases/…

Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 (anti-ILT2) in Advanced Solid Tumors
investor.agenusbio.com/news-releases/…

Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report on August 9th: investor.agenusbio.com/news-releases/…

July is #SarcomaAwareness Month, and Agenus is proud to be supporting @curesarcoma's work to raise awareness and advocate for patients. Agenus is also proud to contribute to the #IO research we believe has the potential to change patient outcomes and reshape disease treatment.

Read more about our journey to ESMO GI, and the impact we hope our botensilimab data has on MSS CRC research, over at WBZ | CBS Boston News: cbsnews.com/boston/news/sp…

Agenus to Participate in William Blair's Biotech Focus Conference: investor.agenusbio.com/news-releases/…

Thank you to our team in Barcelona and beyond, who made our time at @ESMOWORLDGI so outstanding. We look forward to seeing where #innovation in the field of #IO research takes us!